Activation of IL6/IGFIR confers poor prognosis of HBV-related hepatocellular carcinoma through induction of OCT4/NANOG expression.
about
IL-6 Plays a Crucial Role in HBV InfectionGenetic and epigenetic aspects of initiation and progression of hepatocellular carcinomaInflammation Shapes Stem Cells and Stemness during Infection and BeyondInflammation Promotes Expression of Stemness-Related Properties in HBV-Related Hepatocellular CarcinomaTGF-βI Regulates Cell Migration through Pluripotent Transcription Factor OCT4 in Endometriosis.Long noncoding RNA lncTCF7, induced by IL-6/STAT3 transactivation, promotes hepatocellular carcinoma aggressiveness through epithelial-mesenchymal transitionCytokine levels contribute to the pathogenesis of minimal hepatic encephalopathy in patients with hepatocellular carcinoma via STAT3 activation.A novel anti-cancer agent Icaritin suppresses hepatocellular carcinoma initiation and malignant growth through the IL-6/Jak2/Stat3 pathway.Comprehensive profiling of novel microRNA-9 targets and a tumor suppressor role of microRNA-9 via targeting IGF2BP1 in hepatocellular carcinoma.ILs-3, 6 and 11 increase, but ILs-10 and 24 decrease stemness of human prostate cancer cells in vitro.High expression of myoferlin is associated with poor outcome in oropharyngeal squamous cell carcinoma patients and is inversely associated with HPV-statusInterleukin-6 enhances cancer stemness and promotes metastasis of hepatocellular carcinoma via up-regulating osteopontin expression.Transcription factor Oct4 promotes osteosarcoma by regulating lncRNA AK055347.CD133+ cancer stem cells promoted by VEGF accelerate the recurrence of hepatocellular carcinoma.Ino80 promotes cervical cancer tumorigenesis by activating Nanog expression.Type I insulin-like growth factor receptor signaling in hematological malignancies.8-Bromo-7-methoxychrysin-blocked STAT3/Twist axis inhibits the stemness of cancer stem cell-like cell originated from SMMC-7721 cells.IL6-mediated inflammatory loop reprograms normal to epithelial-mesenchymal transition+ metastatic cancer stem cells in preneoplastic liver of transforming growth factor beta-deficient β2-spectrin+/- mice.Identification of novel OCT4 genetic variant associated with the risk of chronic hepatitis B in a Korean population.Hepatocellular carcinoma: from hepatocyte to liver cancer stem cellA Novel Role For Nanog As An Early Cancer Risk Marker In Patients With Laryngeal Precancerous LesionsDioxin Receptor Adjusts Liver Regeneration After Acute Toxic Injury and Protects Against Liver Carcinogenesis.Senescence-Inflammatory Regulation of Reparative Cellular Reprogramming in Aging and Cancer.Bazedoxifene enhances the anti-tumor effects of cisplatin and radiation treatment by blocking IL-6 signaling in head and neck cancer.IGF-1R Promotes Symmetric Self-Renewal and Migration of Alkaline Phosphatase+ Germ Stem Cells through HIF-2α-OCT4/CXCR4 Loop under Hypoxia.Transforming growth factor-β in liver cancer stem cells and regeneration.High expression of OCT4 is frequent and may cause undesirable treatment outcomes in patients with acute myeloid leukemia.IL-17A promotes the invasion-metastasis cascade via the AKT pathway in hepatocellular carcinoma.Bioinformatic analysis and prediction of the function and regulatory network of long non-coding RNAs in hepatocellular carcinoma.Endogenous authentic OCT4A proteins directly regulate FOS/AP-1 transcription in somatic cancer cells."Social Life" of Senescent Cells: What Is SASP and Why Study It?Chronic Niche Inflammation in Endometriosis-Associated Infertility: Current Understanding and Future Therapeutic StrategiesUpregulation of stem cell markers ALDH1A1 and OCT4 as potential biomarkers for the early detection of cervical carcinomaOct3/4 is potentially useful for the suppression of the proliferation and motility of hepatocellular carcinoma cells
P2860
Q26774879-5560A7EC-44C7-4A25-B93C-510439CAC007Q26784412-1A68DE73-D7B2-4213-8144-8329C2524A98Q28074480-4C5F5FEE-ACF6-48E6-A530-8E4C1CB10AA7Q28550411-E0AFC911-BC7A-4E67-97CB-CFC56A1D382DQ35870859-DF486E5E-76E9-464E-A4CF-A2771B426AA9Q36144048-59465325-B07E-4E9A-B751-AB4EA7770658Q36499677-D561969E-EC77-4417-8FD7-BA55EE09369CQ36544739-D33C0038-EF8F-4EEE-A18E-C339B982DD48Q36561669-45D5AF1D-F132-433F-A151-C49737296579Q36618978-EB55CE46-B48C-47C4-B439-093B55A9056CQ37109848-B6C69508-C49B-4898-8565-485AA9AF6E1DQ37298268-F1FA9462-8602-4E2B-BA1E-D27A5AC0A5C2Q37593970-C9A65522-3EB7-462C-929E-512E47CD62C9Q37612276-75D01E0C-4774-48C7-81DC-BF3305FA6929Q37687811-02D7F17D-8EC9-4A9F-8F3B-F4926E8B8D6CQ37702186-C878EDD1-309A-4E2B-98DD-2D437AA6FCA0Q38709245-D2700343-FD65-483E-878D-50AE96072497Q38730296-057807E3-48C0-4CF2-B05B-E7E769C57B5DQ40551445-E3CFF1DE-9196-43D3-9BD3-B51DB89DEE98Q40766851-7AD2EDB6-BF6F-4A5C-860E-7129395DCCFCQ41319418-DCEBAF34-1B2B-4680-B4CD-3EAC2A52B10AQ41620081-43A67A31-3719-4CD6-A5D7-EADDE3D24E87Q42121084-09E80DAC-85C0-49CE-98F9-8400B9A07030Q42133030-294FCF52-DA8D-4A06-BC66-52E24F9D33C4Q47226479-E8CF4ACE-AFAD-439B-B02E-E0C50F6B18B5Q52699075-91C2481A-FE17-47DD-82A6-107F61025FA1Q53436427-4CB1D44B-B398-4346-9A24-DC479B1C053BQ54940618-5C9B937B-D043-4395-9FC3-D28C6211F6B9Q54979499-40A929FB-4C80-46C1-B1E9-0B5D7A24C54FQ55296648-EAF49E32-FB8B-4948-9DDA-A2C5B68B5A8EQ55322104-4076FFD1-E6AA-454B-858F-5F79580E7635Q57169681-954836F4-92E2-4D4F-985F-A0044F70F19DQ57788852-EC893F3C-CEB6-4CBC-B842-8A4EC6B0038BQ58788854-4F911E0C-BBB8-4347-9F58-EE7DB070A64A
P2860
Activation of IL6/IGFIR confers poor prognosis of HBV-related hepatocellular carcinoma through induction of OCT4/NANOG expression.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Activation of IL6/IGFIR confer ...... tion of OCT4/NANOG expression.
@en
type
label
Activation of IL6/IGFIR confer ...... tion of OCT4/NANOG expression.
@en
prefLabel
Activation of IL6/IGFIR confer ...... tion of OCT4/NANOG expression.
@en
P2093
P50
P1476
Activation of IL6/IGFIR confer ...... ction of OCT4/NANOG expression
@en
P2093
Jun-Jen Liu
Kam-Fai Lee
Liang-Mou Kuo
Pey-Jium Chang
Shui-Yi Tung
Tao-Hsin Tung
Te-Sheng Chang
Wei-Chi Su
P304
P356
10.1158/1078-0432.CCR-13-3274
P407
P577
2015-01-01T00:00:00Z